Cargando…
Thromboprophylaxis in COVID‐19: Weight and severity adjusted intensified dosing
BACKGROUND: Venous thromboembolism (VTE) frequently occurs in hospitalized patients with coronavirus disease 2019 (COVID‐19). The optimal dose of anticoagulation for thromboprophylaxis in COVID‐19 is unknown. AIMS: To report VTE incidence and bleeding before and after implementing a hospital‐wide in...
Autores principales: | Engelen, Matthias M., Vandenbriele, Christophe, Spalart, Valérie, Martens, Caroline P., Vandenberk, Bert, Sinonquel, Pieter, Lorent, Natalie, De Munter, Paul, Willems, Rik, Wauters, Joost, Wilmer, Alexander, Dauwe, Dieter, Gunst, Jan, Guler, Ipek, Janssens, Stefan, Martinod, Kimberly, Pieters, Griet, Peerlinck, Kathelijne, Verhamme, Peter, Vanassche, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980774/ https://www.ncbi.nlm.nih.gov/pubmed/35415384 http://dx.doi.org/10.1002/rth2.12683 |
Ejemplares similares
-
Repolarization abnormalities on admission predict 1-year outcome in COVID-19 patients
por: Vandenberk, Bert, et al.
Publicado: (2021) -
Correction to: A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study
por: Vanassche, T., et al.
Publicado: (2020) -
A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study
por: Vanassche, T., et al.
Publicado: (2020) -
Modulation of thromboinflammation in hospitalized COVID‐19 patients with aprotinin, low molecular weight heparin, and anakinra: The DAWn‐Antico study
por: Engelen, Matthias M., et al.
Publicado: (2022) -
Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants
por: Geldhof, Vincent, et al.
Publicado: (2014)